Centessa Pharmaceuticals announces an underwritten public offering of American Depositary Shares, subject to market conditions.
Quiver AI Summary
Centessa Pharmaceuticals plc has announced the commencement of an underwritten public offering of American Depositary Shares (ADSs), with each ADS representing one ordinary share. The company is offering all of the ADSs in the offering and plans to give underwriters a 30-day option to purchase an additional 15% of the ADSs. The offering is subject to market conditions, and there is no guarantee of its completion or terms. Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are leading the offering, with a registration statement already filed with the SEC. Additionally, Centessa is focused on developing transformative therapies for neurological disorders and includes forward-looking statements regarding the offering's completion and terms. The company has also noted that this release does not constitute an offer to sell securities.
Potential Positives
- Centessa Pharmaceuticals has initiated an underwritten public offering of American Depositary Shares, which can provide potential capital to fund ongoing research and development efforts.
- The company is granting underwriters a 30-day option to purchase up to an additional 15% of the ADSs, indicating confidence in market demand for the offering.
- This offering is linked to a registration statement that was already filed and became effective, streamlining the fundraising process and potentially reducing regulatory hurdles.
- Centessa's focus on pioneering new therapies for neurological and neuropsychiatric disorders highlights its commitment to developing innovative solutions, which can enhance its market position and attract investor interest.
Potential Negatives
- Commencement of a public offering may indicate potential liquidity issues, raising concerns among investors about the company's financial health.
- The lack of assurance regarding the completion, size, or terms of the offering could create uncertainty, potentially impacting investor confidence.
- The press release includes disclaimers about risks and uncertainties, which may suggest that the company's future operations and financial outcomes are vulnerable to market conditions.
FAQ
What is the purpose of Centessa Pharmaceuticals' public offering?
Centessa Pharmaceuticals is conducting a public offering of American Depositary Shares to raise funds for its clinical-stage programs.
Who are the underwriters for this public offering?
Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are the joint book-running managers for the offering.
What is the size of the offering by Centessa Pharmaceuticals?
The exact size of the offering has not been disclosed, but there is a provision for a 30-day option for underwriters to purchase an additional 15% of ADSs.
Where can I find the prospectus for Centessa's public offering?
The preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available on their website, http://www.sec.gov.
What are the risks associated with this public offering?
Risks include market conditions and other uncertainties that could affect the completion and timing of the public offering.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CNTA Insider Trading Activity
$CNTA insiders have traded $CNTA stock on the open market 24 times in the past 6 months. Of those trades, 2 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $CNTA stock by insiders over the last 6 months:
- ARJUN GOYAL has made 2 purchases buying 462,585 shares for an estimated $5,865,242 and 0 sales.
- SAURABH SAHA (Chief Executive Officer) has made 0 purchases and 3 sales selling 165,000 shares for an estimated $2,269,536.
- TIA L BUSH (Chief Technology & Quality Ofc) has made 0 purchases and 3 sales selling 84,792 shares for an estimated $1,885,840.
- IQBAL J HUSSAIN (General Counsel) has made 0 purchases and 7 sales selling 76,000 shares for an estimated $1,466,806.
- MARIO ALBERTO ACCARDI (President, Orexin Program) has made 0 purchases and 6 sales selling 46,494 shares for an estimated $851,596.
- GREGORY M WEINHOFF (Chief Business Officer) has made 0 purchases and 3 sales selling 30,000 shares for an estimated $422,465.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CNTA Hedge Fund Activity
We have seen 61 institutional investors add shares of $CNTA stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HOLOCENE ADVISORS, LP removed 2,255,679 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $29,639,622
- PERCEPTIVE ADVISORS LLC removed 1,893,460 shares (-62.3%) from their portfolio in Q2 2025, for an estimated $24,880,064
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,752,847 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $23,032,409
- FEDERATED HERMES, INC. added 1,749,650 shares (+inf%) to their portfolio in Q3 2025, for an estimated $42,429,012
- RTW INVESTMENTS, LP added 1,479,836 shares (+2959.7%) to their portfolio in Q2 2025, for an estimated $19,445,045
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,449,000 shares (+20.8%) to their portfolio in Q2 2025, for an estimated $19,039,860
- BAKER BROS. ADVISORS LP removed 1,227,178 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $16,125,118
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CNTA Analyst Ratings
Wall Street analysts have issued reports on $CNTA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 11/07/2025
- Stephens & Co. issued a "Overweight" rating on 10/28/2025
- Guggenheim issued a "Buy" rating on 10/06/2025
- Chardan Capital issued a "Buy" rating on 08/12/2025
- Needham issued a "Buy" rating on 05/28/2025
To track analyst ratings and price targets for $CNTA, check out Quiver Quantitative's $CNTA forecast page.
$CNTA Price Targets
Multiple analysts have issued price targets for $CNTA recently. We have seen 6 analysts offer price targets for $CNTA in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Benjamin Burnett from Wells Fargo set a target price of $30.0 on 11/07/2025
- Sudan Loganathan from Stephens & Co. set a target price of $35.0 on 10/28/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $28.0 on 10/06/2025
- Rudy Li from Chardan Capital set a target price of $30.0 on 08/12/2025
- Danielle Brill from Truist Securities set a target price of $30.0 on 07/21/2025
- Ami Fadia from Needham set a target price of $35.0 on 05/28/2025
Full Release
BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co., Truist Securities and LifeSci Capital are acting as co-lead managers.
The ADSs are being offered pursuant to a registration statement on Form S-3 that was filed with the Securities and Exchange Commission (“SEC”) on September 11, 2024 and became automatically effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at [email protected] ; or Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525 ext. 6105, email: [email protected] ; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, telephone: (888) 474-0200, email: [email protected] ; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: at (212) 518-9544, or by emailing [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders.
Forward Looking Statements
This press release contains forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including those relating to Centessa’s expectations regarding the completion, timing and size of the public offering and its expectations with respect to granting the underwriters a 30-day option to purchase additional ADSs. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to completion of the proposed public offering on the anticipated terms, or at all, include, but are not limited to, market conditions and the satisfaction of customary closing conditions related to the proposed public offering. Risks concerning our programs and operations are described in additional detail in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other reports, which are on file with the U.S. Securities and Exchange Commission. We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
[email protected]
